HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Is there a protective role of progestogens on the proliferation of human ovarian cancer cells in the presence of growth factors?

AbstractPURPOSE OF INVESTIGATION:
The role of progestogens in the genesis of ovarian cancer remains unclear although a rather protective behaviour has been suggested. Epidemiological studies indicate a possible increase in the risk for combined estrogen/progestin as compared to estrogen alone. It is ambigious whether a difference exists within the various progestogens. Apart from sex steroids, growth factors play a crucial role in the genesis of ovarian cancer, although as yet little investigated. In the present study we have explored the effect of progesterone (P), medroxyprogesterone acetate (MPA) and norethisterone (NET) on the proliferation of human ovarian cancer cells alone and in the presence of growth factors.
METHODS:
For the experiments human ovarian cancer cells (OVCAR-3) were used. The progestogens were tested at the concentrations of 0.01 to 10 microM. The growth factor mixture consisted of EGF, FGF and IGF-I, each at a concentration of 10 pM. The incubation time was three or seven days. Proliferation rate was measured by an ATP-assay.
RESULTS:
After three days' incubation the growth factors induced an increase in the proliferation rate of about 50%. Progesterone alone did not show any significant change as compared to the control values, whereas NET and MPA elicited a significant increase at 1 and 10 microM and at 1 microM, respectively. In the presence of growth factors none of the progestogens was able to inhibit the proliferative stimulation. After seven days' incubation the growth factors still showed an increase of about 50%. MPA alone had an inhibitory effect at 10 microM, for NET and P no effects were observed. Again in the presence of growth factors no progestogen was able to show an inhibitory effect.
CONCLUSION:
Our results indicate that progestogens do not have a protective role on the growth of pre-existing ovarian cancer cells, at least in the presence of growth factors. Further investigations are worthwile to evaluate possible differences between the effect of the various progestogens.
AuthorsH Seeger, D Wallwiener, A O Mueck
JournalEuropean journal of gynaecological oncology (Eur J Gynaecol Oncol) Vol. 27 Issue 2 Pg. 139-41 ( 2006) ISSN: 0392-2936 [Print] Italy
PMID16620055 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents, Hormonal
  • Insulin-Like Growth Factor Binding Proteins
  • Progestins
  • Protective Agents
  • Fibroblast Growth Factors
  • Epidermal Growth Factor
  • Medroxyprogesterone Acetate
  • Norethindrone
Topics
  • Analysis of Variance
  • Antineoplastic Agents, Hormonal (pharmacology)
  • Cell Line, Tumor (drug effects)
  • Cell Proliferation (drug effects)
  • Epidermal Growth Factor (pharmacology)
  • Female
  • Fibroblast Growth Factors (pharmacology)
  • Humans
  • In Vitro Techniques
  • Insulin-Like Growth Factor Binding Proteins (pharmacology)
  • Medroxyprogesterone Acetate (pharmacology)
  • Norethindrone (pharmacology)
  • Ovarian Neoplasms (drug therapy, metabolism)
  • Progestins (pharmacology)
  • Protective Agents

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: